Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy
Not Applicable
Completed
- Conditions
- Muscle Hypertrophy in Healthy Young Men
- Interventions
- Registration Number
- NCT02551276
- Lead Sponsor
- University of Copenhagen
- Brief Summary
Studies in animals have shown that beta2-adrenoceptor activation with selective agonists regulates protein metabolism and muscle growth in skeletal and cardiac muscle tissue. These effects may be mediated by cAMP/PKA dependent activation of several downstream sites that modulate protein synthesis and breakdown. While the role of beta2-adrenoceptor signaling is well-described in animals, it is inadequately explored in humans. The purpose of the study is thus to investigate the effect of chronic beta2-adrenergic stimulation (cAMP/PKA-signaling) on muscle hypertrophy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 42
Inclusion Criteria
- Physical active
- Non-smokers
- Non-asthmatics
- No chronic diseases
- Informed consent
Exclusion Criteria
- Smoker
- Allergy towards study drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control Resistance training Placebo and resistance training for 10 weeks Control Placebo Placebo and resistance training for 10 weeks Experimental Resistance training Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks Experimental Salbutamol Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
- Primary Outcome Measures
Name Time Method Skeletal Muscle Hypertrophy (lean body mass in Kilograms) 2 days Lean body mass (kg) will be measured at two different days by Dual X-ray absorbance (DXA)
- Secondary Outcome Measures
Name Time Method Left Ventricular Hypertrophy (mass in grams) 1 day Left Ventricular Mass (g) will be measured by echocardiography of the heart